Deals channel feed – Endpoints News

Deals channel feed

Paratek shares soar as the antibiotic developer posts a ‘for sale’ sign

8 years ago

Biotech M&A barely showing sign of a pulse so far in 2017

8 years ago

Melinta will beef up its antibiotics pipeline after a merger with troubled Cempra

8 years ago

Mallinckrodt bags late-stage infantile jaundice drug in $425M InfaCare buyout deal

8 years ago

LabCorp nabs Chiltern, boosting its big Covance CRO group to 20K-plus staffers in $1.2B deal

8 years ago

Evotec expands global discovery, development ops with $300M Aptuit buyout

8 years ago

Mitsubishi Tanabe bags NeuroDerm and its PhIII Parkinson’s program for $1.1B

8 years ago

What's holding back biotech M&A? SVB tracks a trend and calls a comeback

8 years ago

Biotech M&A? Novartis chief Jimenez says he’s sticking to the under-$1B aisle for now

8 years ago

Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive

8 years ago

Sanofi finally manages to close on a buyout – but it’s not a game changer

8 years ago

Gilead buy Vertex? A golden oldie in the M&A buzz circuit gets fresh air time

8 years ago

Buyout Buzz: Sanofi, Gilead rumors keep the fire burning under a boiling Tesaro buyout story

8 years ago

Tesaro is reportedly on the auction block, but who can afford it?

8 years ago

It’s all quite satisfactory, merci: Sanofi chairman Serge Weinberg shrugs off growing calls for an M&A deal

9 years ago

So what’s holding back Pfizer and Gilead from the really big M&A deals we’ve all been waiting for?

9 years ago

The top 9 overseas accounts in biopharma hold $133B in M&A firepower

9 years ago

Politics, pricing controversy, tax reform and steep valuations conspire to confuse Sanofi’s M&A strategy

9 years ago

Sucampo bags rare disease player Vtesse in $200M buyout agreement

9 years ago

Astellas swoops in on a mid-stage drug for hot flashes in $860M biotech buyout deal

9 years ago

Report — Sanofi close to bagging Flexion in a looming $1B-plus buyout, shares rocket up

9 years ago

Texas biotech executes a reverse merger with a battered Threshold

9 years ago

Meacham’s manifesto to Gilead: It’s time to do something dramatic — buy, bag or burn

9 years ago

Global Blood Therapeutics shares spike on buzz about a potential Novo buyout

9 years ago

First page Previous page 111 112 113114115 116 Next page Last page